⌘K
t
Cizzle Biotechnology Holdings plc announced on 27 October 2025 that it has changed its registered office and UK head office. The new address is c/o Ampa Holdings LLP, Level 19, The Shard, 32 London Bridge Street, London, SE1 9SG, effective immediately.
| Date | 27 Oct 2025 |
| Time | 11:32:31 |
| Category | Corporate updates |
| ID | 9588E |
27 October 2025
Cizzle Biotechnology Holdings plc
("Cizzle", "Cizzle Biotechnology", or the "Company")
Change of Registered Office
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, confirms that it has changed its registered office and UK head office from 6th Floor, 60 Gracechurch Street, London, EC3V 0HR, to c/o Ampa Holdings LLP, Level 19, The Shard, 32 London Bridge Street, London, SE1 9SG effective immediately.
Enquiries:
|
Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
|
Allan Syms (Executive Chairman) |
|
|
Allenby Capital Limited |
+44(0) 20 3328 5656 |
|
John Depasquale/Piers Shimwell (Corporate Finance) |
|
|
Amrit Nahal (Sales and Corporate Broking) |
|
|
IFC Advisory Limited |
+44(0) 20 3934 6630 |
|
|
Tim Metcalfe |
|
|
|
Florence Staton |
|
|
About Cizzle Biotechnology
Based on the pioneering work of Professor Coverley and colleagues, on a naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B biomarker is highly associated with the presence of early-stage cancer. The company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.